⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMMX News
Immix Biopharma, Inc. Common Stock
Form 8-K
sec.gov
IMMX
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com
IMMX
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
globenewswire.com
IMMX
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
globenewswire.com
IMMX
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory
globenewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
accessnewswire.com
IMMX